Yohann Loriot is a medical oncologist at the Gustave Roussy Cancer Institute Cancer Campus of the Université Paris-Saclay in the Villejuif commune of Paris, France.
Dr Loriot’s main research interest is the study of the mechanisms mediating progression to lethal disease in cancers of the bladder and prostate with a focus on the development of novel strategies and therapies targeting these conditions at the molecular level.
As a member of the steering committees of several international clinical trials, Dr Loriot has published extensively in his specialized field, and has been instrumental in the development of high-impact publications supporting the approval of therapeutic agents including enzalutamide, abiraterone, and atezolizumab. he also co-led the study that led to the approval of the fibroblast growth factor receptor inhibitor erdafitinib.
He is currently engaged in the development of ancillary studies to help better understand the mechanisms of action of (and resistance to) targeted therapies and checkpoint inhibitors.
EM-15426 - Date of preparation: July 2019